Search hospitals > Wisconsin > Milwaukee
Aurora Cancer Care-Milwaukee West
Claim this profileMilwaukee, Wisconsin 53226
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
200 reported clinical trials
23 medical researchers
Summary
Aurora Cancer Care-Milwaukee West is a medical facility located in Milwaukee, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Aurora Cancer Care-Milwaukee West is involved with conducting 200 clinical trials across 308 conditions. There are 23 research doctors associated with this hospital, such as Rubina Qamar, Thomas J. Saphner, Antony Ruggeri, and Michael A Thompson.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
Top PIs
Rubina QamarAurora Saint Luke's Medical Center1 year of reported clinical research
Expert in Breast Cancer
Expert in Cancer
26 reported clinical trials
72 drugs studied
Thomas J. SaphnerAurora Saint Luke's Medical Center4 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
27 reported clinical trials
57 drugs studied
Antony RuggeriAurora Cancer Care-Milwaukee West4 years of reported clinical research
Studies Cancer
Studies Solid Tumors
14 reported clinical trials
57 drugs studied
Michael A ThompsonAurora Cancer Care-Milwaukee West3 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
12 reported clinical trials
29 drugs studied
Clinical Trials running at Aurora Cancer Care-Milwaukee West
Breast Cancer
Non-Small Cell Lung Cancer
Gastroesophageal Junction Adenocarcinoma
Cancer
Lung Cancer
Prostate Cancer
Gastric Cancer
Bladder Carcinoma
Multiple Myeloma
Renal Cell Carcinoma
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Aurora Cancer Care-Milwaukee West?
Aurora Cancer Care-Milwaukee West is a medical facility located in Milwaukee, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Aurora Cancer Care-Milwaukee West is involved with conducting 200 clinical trials across 308 conditions. There are 23 research doctors associated with this hospital, such as Rubina Qamar, Thomas J. Saphner, Antony Ruggeri, and Michael A Thompson.